Medical oxygen concentrators market seen reaching $7 billion by 2035

Market Research Future projects the global medical oxygen concentrators market will grow from $3.815 billion in 2025 to $7 billion by 2035, driven by rising respiratory disease cases, home healthcare adoption and smarter portable devices. North America leads the market now, while homecare and telehealth-linked oxygen therapy are expected to shape demand through 2035.

Why it matters: - The market is tied to long-term care for chronic respiratory disease, especially COPD. - Growth reflects a broader shift from hospital-based treatment to home-based oxygen therapy and remote monitoring. - The category is expanding as patients, providers and health systems look for more mobile and lower-cost care options.

What happened: - Market Research Future projects the global medical oxygen concentrators market will rise from USD 3.815 billion in 2025 to USD 7.0 billion by 2035. - The forecast implies a 6.26% CAGR over 2025-2035. - The market base was estimated at USD 3.59 billion in 2024. - The report links demand to rising respiratory disease prevalence, home healthcare adoption, device innovation and digital health integration. - The report also says North America led global revenue in 2024, with more than 40% share and about USD 1.44 billion.

The details: - COPD affects about 392 million people worldwide, according to IHME data cited in the report. - Chronic respiratory diseases contribute to more than 454 million cases globally, and COPD causes more than 3 million deaths a year, the report says. - CDC data cited in the report says more than 16 million Americans are diagnosed with COPD. - Portable oxygen concentrators held about 63% of the market in 2024. - Continuous flow technology held about 66% share and was valued at USD 2.15 billion in 2024. - Pulse dose technology was valued at USD 1.44 billion in 2024 and is the fastest-growing technology segment. - Stationary oxygen concentrators were valued at USD 2.09 billion in 2024. - COPD was the largest indication segment with 61% share. - Asthma is projected to reach USD 1.5 billion by 2035. - Hospitals and clinics held 58% of end-user share. - Homecare settings are the fastest-growing end-user segment. - Europe was valued at USD 1.08 billion in 2024, with a 30% share. - Asia-Pacific accounted for about 25% of the global market. - The Middle East and Africa held about 5% of global share.

Between the lines: - The biggest demand driver is not just disease prevalence, but the move toward decentralized care. - WHO data cited in the report says more than 50% of healthcare services for chronic diseases are increasingly delivered at home, and home-based care can reduce costs by up to 30%. - Portable, lightweight and connected devices are becoming more important because they support mobility and adherence. - The report suggests market leaders are competing on technology, distribution and telehealth integration rather than price alone. - Philips, Invacare and AirSep are highlighted as companies pushing product and network expansion. - Philips launched an oxygen concentrator model with AI-based oxygen delivery in August 2025, according to the report. - Invacare expanded distribution in Asia-Pacific in September 2025. - AirSep formed a telehealth partnership in July 2025 to add remote monitoring capabilities.

What's next: - Telehealth integration is expected to become a bigger growth area for remote monitoring and patient management. - Portable oxygen concentrators should keep gaining traction in home healthcare markets. - Hospital procurement contracts and service agreements may become a larger commercial opportunity. - The report expects continued growth and innovation through 2035 as respiratory disease burden and healthcare spending rise.

The bottom line: - Medical oxygen concentrators are moving from a niche respiratory device category to a core home-care and chronic disease management tool.